eMed®

LUMEN®

A unique health program for *your* unique health journey

Whether you're just starting or already on your GLP-1 journey

30lbs
average **weight loss**[1]

97.9%
Prediabetic members **improved HbA1c markers**[1]

- **Ongoing, independent clinical care**
- **At-home convenience**
- **Branded, FDA-approved medication***
- **24/7 side effect support**
- **Reminders & progress tracking**
- **Lifestyle guidance through Thrive Global**



A more supportive way to lose weight

Whether you're starting a GLP-1 for the first time or already taking one, eMed provides the clinical support you need from the comfort of home. An independent, licensed clinical team supports you throughout your journey with weekly check-ins, ongoing support, and semiannual lab testing.

eMed is more than just GLP-1 medication. It's a GLP-1 team and program designed to keep you on track and moving forward.

The eMed Member Journey

Getting Started | Day 1 - 7




Start Journey
Member enrolls via eMed app and receives screening kit




Medical Intake
Guided, at-home clinical intake procedure

Clinical Review | Week 2+




Clinical Evaluation
Interactive clinical evaluation & results



Rx Issued
FDA approved meds via mail-order pharmacy

Ongoing Care



Progress Tracking
Weekly check-ins, progress tracking, 24/7 side effect support, and health & lifestyle guidance

Scan To Learn More

lumen.com/emed

PROGRAM EARLY REGISTRATION
Current GLP-1 Utilizers
December 14, 2026

PROGRAM LAUNCH & RX DELIVERY BEGINS
January 1, 2027

*Prescription medications are available only after an independent clinical evaluation by a licensed healthcare professional. Eligibility is not guaranteed.
GLP-1 medications are prescription drugs. Important Safety Information: https://www.emed.com/important-safety-information
[1]U.S. Corporate Data Partner, 2026: Based on data from a large U.S. employer client (N=638 ; matched lab cohort N=318 at 6 months). Individual results will vary; outcomes may differ across employer populations.